Abstracts tagged "hydroxychloroquine and systemic lupus erythematosus (SLE)"

Abstract Number: 569 • 2013 ACR/ARHP Annual Meeting
Hydroxycholorquine Is Cardioprotective In Neonatal Rat Cardiomyocytes Exposed To Simulated Myocardial Ischaemic/Reperfusion Injury.-An Effect Mediated Through ERK Phosphorylation
Lauren Bourke¹, James McCormick², Anastasis Stephanou³ and Yiannis Ioannou⁴, ¹Centre for Rheumatology Research, University College London, London, United Kingdom, ²Clinical & Molecular Genetics Unit, University College London, London, United Kingdom, ³MMBU, University College London, London, United Kingdom, ⁴Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom
Background/Purpose: A significant amount of myocardial damage during a myocardial infarction (MI) occurs during the reperfusion stage which is known as ischaemic reperfusion (I/R) injury…
Abstract Number: 559 • 2013 ACR/ARHP Annual Meeting
Effects Of In Vivo Treatment With Hydroxychloroquine On Endothelial Function In a Murine Model Of Systemic Lupus Erythematosus
Marta Mosca¹, Chiara Tani², Sabrina Vagnani³, Linda Carli^3,4, Rosaria Talarico⁵, Chiara Baldini⁵, Stefano Bombardieri³ and Agostino Virdis⁶, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴GenOMeC PhD, University of Siena, Siena, Italy, ⁵University of Pisa, Rheumatology Unit, Pisa, Italy, ⁶Department of Clinical and Experimental Medicine. University of Pisa, Hypertension Unit, University of Pisa, Pisa, Italy
Background/Purpose: Antimalarial drugs are a cornerstone of treatment of systemic lupus erythematosus (SLE). It has been suggested that antimalarial drugs may have a protective effect…
Abstract Number: 200 • 2013 ACR/ARHP Annual Meeting
Hydroxychloroquine Use Among Systemic Lupus Erythematosus Patients In An Academic Rheumatology Practice
James G. Miceli¹ and Harry D. Fischer², ¹Internal Medicine, Beth Israel Medical Center, New York, NY, ²Division of Rheumatology, Albert Einstein College of Medicine at Beth Israel Medical Center, New York, NY
Background/Purpose: Hydroxychloroquine (HCQ) is a mainstay in the current treatment of systemic lupus erythematosus (SLE). HCQ has been shown to reduce the incidence of SLE…
Abstract Number: 1733 • 2012 ACR/ARHP Annual Meeting
Effect of Hydroxychloroquine (HCQ) On the Annexin A5 Resistance Assay (AnxA5-RA) in Antiphospholipid Antibody (aPL)-Positive Patients: Preliminary Results of an Ongoing Prospective Study
Alana B. Levine¹, Jacob H. Rand², Xiao Xuan Wu³, JoAnn Vega⁴, Glendalee Ramon¹, Stephen L. Lyman⁴, Doruk Erkan¹ and Michael D. Lockshin⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Department of Pathology; Hematology Laboratories, Montefiore Medical Center, Bronx, NY, ³Pathology; Hematology Laboratories, Montefiore Medical Center, Bronx, NY, ⁴Research, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: One proposed mechanism of aPL-mediated thrombosis is disruption of the AnxA5 shield, allowing initiation of coagulation reactions on phospholipid surfaces. The AnxA5-RA measures the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].